Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.

Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, Wan Y, Fan J, Brooks AN, Herman SEM, Ten Hacken E, Taylor-Weiner A, Rassenti LZ, Ghia EM, Kipps TJ, Obeng EA, Cibulskis CL, Neuberg D, Campagna DR, Fleming MD, Ebert BL, Wiestner A, Leshchiner I, DeCaprio JA, Getz G, Reed R, Carrasco RD, Wu CJ, Wang L.

Cancer Cell. 2019 Feb 11;35(2):283-296.e5. doi: 10.1016/j.ccell.2018.12.013. Epub 2019 Jan 31.

2.

Protracted course of disseminated adenovirus disease with necrotizing granulomas in the liver.

Lerner AM, Bennett JE, Pittaluga S, Khil PP, Youn JH, Fahle GA, Frank KM, Dekker JP, Jerussi TD, Sun C, Wiestner A, Gea-Banacloche J.

Diagn Microbiol Infect Dis. 2019 Jan 2. pii: S0732-8893(18)30468-1. doi: 10.1016/j.diagmicrobio.2018.12.012. [Epub ahead of print]

PMID:
30679057
3.

TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.

Dadashian EL, McAuley EM, Liu D, Shaffer AL 3rd, Young RM, Iyer JR, Kruhlak MJ, Staudt LM, Wiestner A, Herman SEM.

Cancer Res. 2019 Jan 15;79(2):360-371. doi: 10.1158/0008-5472.CAN-18-0781. Epub 2018 Nov 29.

PMID:
30498085
4.

Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.

Aue G, Sun C, Liu D, Park JH, Pittaluga S, Tian X, Lee E, Soto S, Valdez J, Maric I, Stetler-Stevenson M, Yuan C, Nakamura Y, Muranski P, Wiestner A.

J Immunol. 2018 Oct 1;201(7):1967-1974. doi: 10.4049/jimmunol.1800570. Epub 2018 Aug 13.

PMID:
30104242
5.

Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies.

Chang J, Peng H, Shaffer BC, Baskar S, Wecken IC, Cyr MG, Martinez GJ, Soden J, Freeth J, Wiestner A, Rader C.

Cancer Immunol Res. 2018 Sep;6(9):1008-1013. doi: 10.1158/2326-6066.CIR-18-0102. Epub 2018 Jul 6.

PMID:
29980538
6.

Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.

Taneja A, Jones J, Pittaluga S, Maric I, Farooqui M, Ahn IE, Wiestner A, Sun C.

Leuk Lymphoma. 2018 Jul 6:1-4. doi: 10.1080/10428194.2018.1480775. [Epub ahead of print] No abstract available.

PMID:
29978754
7.

Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.

Qi J, Li X, Peng H, Cook EM, Dadashian EL, Wiestner A, Park H, Rader C.

Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5467-E5476. doi: 10.1073/pnas.1719905115. Epub 2018 May 29.

8.

Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Pleyer C, Wiestner A, Sun C.

Leuk Lymphoma. 2018 Dec;59(12):2792-2800. doi: 10.1080/10428194.2018.1457147. Epub 2018 May 15.

PMID:
29764250
9.

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.

Robinson HR, Qi J, Cook EM, Nichols C, Dadashian EL, Underbayev C, Herman SEM, Saba NS, Keyvanfar K, Sun C, Ahn IE, Baskar S, Rader C, Wiestner A.

Blood. 2018 Aug 2;132(5):521-532. doi: 10.1182/blood-2018-02-830992. Epub 2018 May 9.

PMID:
29743179
10.

Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytes.

Gunti S, Herman SEM, Gottumukkala RVSRK, Xiong Y, Sun C, Carmona GN, Wiestner A, Notkins AL.

Leuk Lymphoma. 2019 Jan;60(1):242-245. doi: 10.1080/10428194.2018.1464159. Epub 2018 May 9. No abstract available.

PMID:
29741135
11.

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, Lotter J, Housel S, Stetler-Stevenson M, Yuan CM, Maric I, Calvo KR, Nierman P, Hughes TE, Saba NS, Marti GE, Pittaluga S, Herman SEM, Niemann CU, Pedersen LB, Geisler CH, Childs R, Aue G, Wiestner A.

Blood. 2018 May 24;131(21):2357-2366. doi: 10.1182/blood-2017-12-820910. Epub 2018 Feb 26.

PMID:
29483101
12.

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.

Bomben R, Ferrero S, D'Agaro T, Dal Bo M, Re A, Evangelista A, Carella AM, Zamò A, Vitolo U, Omedè P, Rusconi C, Arcaini L, Rigacci L, Luminari S, Piccin A, Liu D, Wiestner A, Gaidano G, Cortelazzo S, Ladetto M, Gattei V.

Haematologica. 2018 May;103(5):849-856. doi: 10.3324/haematol.2017.184325. Epub 2018 Feb 22.

13.

Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Burger JA, Wiestner A.

Nat Rev Cancer. 2018 Mar;18(3):148-167. doi: 10.1038/nrc.2017.121. Epub 2018 Jan 19. Review.

PMID:
29348577
14.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A.

J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.

15.

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.

Landau DA, Sun C, Rosebrock D, Herman SEM, Fein J, Sivina M, Underbayev C, Liu D, Hoellenriegel J, Ravichandran S, Farooqui MZH, Zhang W, Cibulskis C, Zviran A, Neuberg DS, Livitz D, Bozic I, Leshchiner I, Getz G, Burger JA, Wiestner A, Wu CJ.

Nat Commun. 2017 Dec 19;8(1):2185. doi: 10.1038/s41467-017-02329-y.

16.

CLL kinetics in the tumor microenvironment.

Sun C, Wiestner A.

Oncotarget. 2017 Oct 3;8(49):84634. doi: 10.18632/oncotarget.21467. eCollection 2017 Oct 17. No abstract available.

17.

MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.

Saba NS, Wong DH, Tanios G, Iyer JR, Lobelle-Rich P, Dadashian EL, Liu D, Fontan L, Flemington EK, Nichols CM, Underbayev C, Safah H, Melnick A, Wiestner A, Herman SEM.

Cancer Res. 2017 Dec 15;77(24):7038-7048. doi: 10.1158/0008-5472.CAN-17-2485. Epub 2017 Oct 9.

18.

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.

Niemann CU, Mora-Jensen HI, Dadashian EL, Krantz F, Covey T, Chen SS, Chiorazzi N, Izumi R, Ulrich R, Lannutti BJ, Wiestner A, Herman SEM.

Clin Cancer Res. 2017 Oct 1;23(19):5814-5823. doi: 10.1158/1078-0432.CCR-17-0650. Epub 2017 Jun 23.

19.

Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier.

Navarro A, Clot G, Martínez-Trillos A, Pinyol M, Jares P, González-Farré B, Martínez D, Trim N, Fernández V, Villamor N, Colomer D, Costa D, Salaverria I, Martín-Garcia D, Erber W, López C, Jayne S, Siebert R, Dyer MJS, Wiestner A, Wilson WH, Aymerich M, López-Guillermo A, Sánchez À, Campo E, Matutes E, Beà S.

Haematologica. 2017 Sep;102(9):e360-e363. doi: 10.3324/haematol.2016.160374. Epub 2017 May 18. No abstract available.

20.

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.

Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van T' Veer MB, Tjønnfjord GE, Itälä-Remes MA, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MCJ, van Oers MHJ, Geisler CH, Niemann CU.

Leuk Lymphoma. 2017 Oct;58(10):2356-2362. doi: 10.1080/10428194.2017.1285027. Epub 2017 Feb 7.

PMID:
28278728
21.

Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.

Albitar A, Ma W, DeDios I, Estella J, Ahn I, Farooqui M, Wiestner A, Albitar M.

Oncotarget. 2017 Mar 14;8(11):17936-17944. doi: 10.18632/oncotarget.15316.

22.

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.

Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langellotto F, Ambrogio C, Voena C, Wiestner A, Kasar SN, Brown JR, Sun J, Wu CJ, Gostissa M, Alt FW, Chiarle R.

Nature. 2017 Feb 23;542(7642):489-493. doi: 10.1038/nature21406. Epub 2017 Feb 15.

23.

Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.

Shapiro M, Herishanu Y, Katz BZ, Dezorella N, Sun C, Kay S, Polliack A, Avivi I, Wiestner A, Perry C.

Haematologica. 2017 May;102(5):874-882. doi: 10.3324/haematol.2016.148965. Epub 2017 Feb 2.

24.

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.

Herndon TM, Chen SS, Saba NS, Valdez J, Emson C, Gatmaitan M, Tian X, Hughes TE, Sun C, Arthur DC, Stetler-Stevenson M, Yuan CM, Niemann CU, Marti GE, Aue G, Soto S, Farooqui MZH, Herman SEM, Chiorazzi N, Wiestner A.

Leukemia. 2017 Jun;31(6):1340-1347. doi: 10.1038/leu.2017.11. Epub 2017 Jan 11.

25.

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, Stetler-Stevenson M, Soto S, Valdez J, Nierman P, Lotter J, Xi L, Raffeld M, Farooqui M, Albitar M, Wiestner A.

Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.

26.

Pneumocystis jirovecii Pneumonia in a Treatment-Naive Patient With Chronic Lymphocytic Leukemia.

Strich JR, Jerussi TD, Wiestner A, Holland SM.

Infect Dis Clin Pract (Baltim Md). 2016 Nov;24(6):e86-e87.

27.

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.

Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, Mantel R, Smith LL, McClanahan F, Harrington BK, Colomer D, Covey T, Byrd JC, Izumi R, Kaptein A, Ulrich R, Johnson AJ, Lannutti BJ, Wiestner A, Woyach JA.

Clin Cancer Res. 2017 Jun 1;23(11):2831-2841. doi: 10.1158/1078-0432.CCR-16-0463. Epub 2016 Nov 30.

28.

Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibility.

Goldin LR, McMaster ML, Rotunno M, Herman SE, Jones K, Zhu B, Boland J, Burdett L, Hicks B, Ravichandran S, Luke BT, Yeager M, Fontaine L, Goldstein AM, Chanock SJ, Tucker MA, Wiestner A, Marti G, Caporaso NE.

Blood. 2016 Nov 3;128(18):2261-2263. Epub 2016 Sep 14. No abstract available.

29.

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.

Matas-Céspedes A, Vidal-Crespo A, Rodriguez V, Villamor N, Delgado J, Giné E, Roca-Ho H, Menéndez P, Campo E, López-Guillermo A, Colomer D, Roué G, Wiestner A, Parren PW, Doshi P, van Bueren JL, Pérez-Galán P.

Clin Cancer Res. 2017 Mar 15;23(6):1493-1505. doi: 10.1158/1078-0432.CCR-15-2095. Epub 2016 Sep 16.

30.

Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.

Sun C, Gao J, Couzens L, Tian X, Farooqui MZ, Eichelberger MC, Wiestner A.

JAMA Oncol. 2016 Dec 1;2(12):1656-1657. doi: 10.1001/jamaoncol.2016.2437. No abstract available.

31.

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.

Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J.

Blood. 2016 Oct 13;128(15):1940-1943. Epub 2016 Aug 8.

32.

Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.

Saleh LM, Wang W, Herman SE, Saba NS, Anastas V, Barber E, Corrigan-Cummins M, Farooqui M, Sun C, Sarasua SM, Zhao Z, Abousamra NK, Elbaz O, Abdelghaffar HA, Wiestner A, Calvo KR.

Leukemia. 2017 Feb;31(2):340-349. doi: 10.1038/leu.2016.181. Epub 2016 Jun 24.

PMID:
27431016
33.

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Reply.

Herman SE, Wiestner A.

Clin Cancer Res. 2016 Jul 1;22(13):3412. doi: 10.1158/1078-0432.CCR-16-0605. No abstract available.

34.

Choosing frontline chemoimmunotherapy for CLL.

Wiestner A.

Lancet Oncol. 2016 Jul;17(7):852-854. doi: 10.1016/S1470-2045(16)30118-8. Epub 2016 May 20. No abstract available.

PMID:
27216275
35.

Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.

Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, Weniger MA, Skarzynski M, Gyamfi J, Fontan L, Melnick A, Grant C, Roschewski M, Navarro A, Beà S, Pittaluga S, Dunleavy K, Wilson WH, Wiestner A.

Blood. 2016 Jul 7;128(1):82-92. doi: 10.1182/blood-2015-11-681460. Epub 2016 Apr 28.

36.

Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.

Herman SE, Wiestner A.

Semin Oncol. 2016 Apr;43(2):222-32. doi: 10.1053/j.seminoncol.2016.02.007. Epub 2016 Feb 8. Review.

37.

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.

Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA.

Haematologica. 2016 Jun;101(6):e254-8. doi: 10.3324/haematol.2015.138289. Epub 2016 Mar 24. No abstract available.

38.

Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.

Bitar C, Farooqui MZ, Valdez J, Saba NS, Soto S, Bray A, Marti G, Wiestner A, Cowen EW.

JAMA Dermatol. 2016 Jun 1;152(6):698-701. doi: 10.1001/jamadermatol.2016.0225.

39.

Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Lipsky AH, Lozier JN, Wiestner A.

Haematologica. 2016 Mar;101(3):e124-5. doi: 10.3324/haematol.2015.140558. No abstract available.

40.

Under the microscope: CCL3 and T cells in the microenvironment of chronic lymphocytic leukemia.

Sun C, Wiestner A.

Leuk Lymphoma. 2016;57(3):501-2. doi: 10.3109/10428194.2015.1085979. Epub 2015 Dec 23. No abstract available.

PMID:
26695886
41.

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.

Niemann CU, Herman SE, Maric I, Gomez-Rodriguez J, Biancotto A, Chang BY, Martyr S, Stetler-Stevenson M, Yuan CM, Calvo KR, Braylan RC, Valdez J, Lee YS, Wong DH, Jones J, Sun C, Marti GE, Farooqui MZ, Wiestner A.

Clin Cancer Res. 2016 Apr 1;22(7):1572-82. doi: 10.1158/1078-0432.CCR-15-1965. Epub 2015 Dec 9.

42.

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Wiestner A.

Haematologica. 2015 Dec;100(12):1495-507. doi: 10.3324/haematol.2014.119123. Review.

43.

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.

Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K, Sun C, Valdez J, Niemann CU, Herman SE, Saba N, Soto S, Marti G, Uzel G, Holland SM, Lozier JN, Wiestner A.

Haematologica. 2015 Dec;100(12):1571-8. doi: 10.3324/haematol.2015.126672. Epub 2015 Oct 1.

44.

PROLONGing remissions in patients with CLL.

Wiestner A.

Lancet Oncol. 2015 Oct;16(13):1282-4. doi: 10.1016/S1470-2045(15)00219-3. Epub 2015 Sep 13. No abstract available.

PMID:
26377301
45.

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.

Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SE, Salem D, Stetler-Stevenson M, Yuan C, Kardava L, Moir S, Maric I, Valdez J, Soto S, Marti GE, Farooqui MZ, Notkins AL, Wiestner A, Aue G.

Blood. 2015 Nov 5;126(19):2213-9. doi: 10.1182/blood-2015-04-639203. Epub 2015 Sep 3.

46.

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

Skarzynski M, Niemann CU, Lee YS, Martyr S, Maric I, Salem D, Stetler-Stevenson M, Marti GE, Calvo KR, Yuan C, Valdez J, Soto S, Farooqui MZ, Herman SE, Wiestner A.

Clin Cancer Res. 2016 Jan 1;22(1):86-95. doi: 10.1158/1078-0432.CCR-15-1304. Epub 2015 Aug 17.

47.

Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.

Herman SE, Mustafa RZ, Jones J, Wong DH, Farooqui M, Wiestner A.

Clin Cancer Res. 2015 Oct 15;21(20):4642-51. doi: 10.1158/1078-0432.CCR-15-0781. Epub 2015 Jun 18.

48.

Nomenclature of Toso, Fas apoptosis inhibitory molecule 3, and IgM FcR.

Kubagawa H, Carroll MC, Jacob CO, Lang KS, Lee KH, Mak T, McAndrews M, Morse HC 3rd, Nolan GP, Ohno H, Richter GH, Seal R, Wang JY, Wiestner A, Coligan JE.

J Immunol. 2015 May 1;194(9):4055-7. doi: 10.4049/jimmunol.1500222.

49.

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.

Leshchenko VV, Kuo PY, Jiang Z, Weniger MA, Overbey J, Dunleavy K, Wilson WH, Wiestner A, Parekh S.

Oncotarget. 2015 Sep 29;6(29):27332-42. doi: 10.18632/oncotarget.2903.

50.

BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.

Wiestner A.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):125-34. doi: 10.1182/asheducation-2014.1.125. Epub 2014 Nov 18. Review.

PMID:
25696845

Supplemental Content

Loading ...
Support Center